



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10591,174
Filing Date: August 30, 2006
Applicant: Jan GUNZINGER et al.
Group Art Unit: TBA
Examiner: TBA
Title: TETRAHYDROISOQUINOLINE AND TETRAHYDROBENZAZEPINE
DERIVATIVES AS IGF-1R INHIBITORS
Attorney Docket: 6170-000010/US

Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314
Mail Stop Amendment

November 6, 2006

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant hereby submits an Information Disclosure Statement for consideration by the Examiner.

I. **LIST OF PATENTS, PUBLICATIONS, AND OTHER INFORMATION**

The patents, publications and other information submitted for consideration by the Office (except unpublished U.S. patent applications) are listed on Form PTO-1449 attached hereto.

II. **COPIES**

A. ☒ Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed, other than U.S. patents and U.S. patent application publications unless required by the Office; (iii) for each cited pending unpublished U.S. application listed below in Section IV, the application specification including the claims, and any drawing of the application, or that portion of the application which caused it to be listed including any claims directed to that portion; and (iv) all other information or that portion which caused it to be listed.

B. ☐ Any patents, publications or other information which are listed on Form PTO-1449 or on the copies of Form PTO-892, but which are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Serial Number

U.S. Filing Date

C. ☐ Because the present application was/is being filed after June 30, 2003, no copies of the U.S. patents or U.S. patent application publications which are listed on the attached Form PTO-1449 are enclosed pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(i). Any foreign patent documents or non-patent literature listed on the attached Form PTO-1449 are enclosed herewith.

D. ☐ This is a PCT application in the entry of the National Phase in the United States. A copy of the International Search Report is attached for the Examiner's information. The documents listed on the International Search Report are listed on the attached Form PTO-1449 for consideration by the Examiner and for listing on any patent resulting from this application. Since the International Search Report was from the US, EPO, or JPO search authorities, copies of these references should have been supplied to the USPTO under the trilateral agreement and are believed to be in the file of the above-identified application. (MPEP 1893.03(g))

III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

A. ☒ Except as may be indicated below in (B), all of the patents, publications or other information are in the English language (concise explanation not required).

B. ☐ A concise explanation of the relevance of each patent, publication or other information listed that is not in the English language is as follows (see 37 C.F.R. § 1.98(a)(3)):

1. ☐ See the attached foreign patent office communication from a counterpart foreign application:
2. ☐ English translations are provided for:
3. ☐ Other:

C. ☐ The following additional information is provided for the Examiner's consideration.

IV. CROSS REFERENCE TO RELATED APPLICATION(S)

A. ☐ The Examiner is advised that the following co-pending application(s) contain(s) subject matter that may be related to the present application. By bringing this(these) application(s) to the Examiner's attention, Applicant(s) does(do) not waive the confidentiality provisions of 35 U.S.C. § 122.

Serial No.

Filing Date

Art Unit

V. THIS IDS IS BEING FILED UNDER

A. ☒ 37 C.F.R. § 1.97(b): (check only one box)

1. ☒ within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. § 1.53(d) (37 C.F.R. § 1.97(b)(1)). No fee or certification is required.
2. ☐ within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or certification is required.
3. ☐ before the mailing of a first Office Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below; or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).
4. ☐ before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No fee or certification is required.

B. ☐ 37 C.F.R. § 1.97(c): (check only one box)

- ☐ before the mailing date of either any Final Office Action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution.
1. ☐ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).
 2. ☐ See the certification below. No fee is required.

C. ☐ 37 C.F.R. § 1.97(d):

- ☐ after the mailing date of either a Final Office Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, yet on or before payment of the issue fee.
1. ☐ See the certification below. A fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e): (check only one box)

The undersigned hereby certifies that:

- A. ☐ each item of information contained in this IDS was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS (See 37 C.F.R. § 1.97(e)(1)). See further statement under 37 C.F.R. § 1.704(d) below in section VII, if applicable; or
- B. ☐ no item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this IDS (See 37 C.F.R. § 1.97(e)(2)).
- C. ☐ Some of the items of information were first cited in a communication from a foreign patent office. As to this information, the undersigned hereby certifies that each item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this IDS.

VII. STATEMENT UNDER 37 C.F.R. § 1.704(d)

The undersigned hereby states that:

☐ each item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this IDS.

VIII. PAYMENT OF FEES (check only one box)

- A. ☒ No fee is believed to be due in light of the above-noted status or above-provided certification.
- B. ☐ A check in the amount of \$180.00 is enclosed for the above-identified fee.
- C. ☐ Please charge Deposit Account No. 08-0750 in the amount of \$180.00 for the above-indicated fee. A duplicate copy of this paper is attached.

The above references are being cited only in the interest of candor and without any admission that they constitute statutory prior art, contain matter which anticipates the invention, or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art. Furthermore, this Information Disclosure Statement shall not be construed as a representation that a search has been made.

If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 08-0750.

Please charge any additional fees or credit any overpayment pursuant to 37 C.F.R. §§ 1.16 or 1.17 to Deposit Account No. 08-0750.

Respectfully submitted,

HARNES, DICKEY, & PIERCE, P.L.C.


By  _____
John A. Castellano, Reg. No. 35,094

P.O. Box 8910
Reston, Virginia 20195
(703) 668-8000

JAC/pw

Enclosures: ☒ Form PTO-1449(s) (1 sheet(s))
☒ Documents
☐ Foreign Search Report
☐ Fee
☐ Other:

FORM HDP-1449 (Based on Form PTO-1449)



PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 1 of 2

ATTORNEY DOCKET NO.

SERIAL NO.

6170-000010/US

10/591,174

APPLICANT

Jan GUNZINGER et al.

FILING DATE

GROUP

August 30, 2006

TBA

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)


Ref. Desig.	Examiner's Initials	
		Ji Sun Lee et al., "Synthesis of 1,2,3,4-Tetrahydroisoquinoline-2-sulfonic Acids," <i>Bull Korean Chem. Soc.</i> , Vol. 24, No. 7, pp. 1041-1044 (2003).
		T.E. Adams et al., "Structure and function of the type 1 insulin-like growth factor receptor," <i>CMLS Cell Mol. Life Sci.</i> , Vol. 57, pp. 1050-1093 (2000).
		Renato Baserga et al., "The IGF-I receptor in cell growth, transformation and apoptosis," <i>Biochimica et Biophysica Acta</i> , Vol. 1332, pp. F105-F126 (1997).
		Thea Kalebic et al., "In Vivo Treatment with Antibody against IGF-1 Receptor Suppresses Growth of Human Rhabdomyosarcoma and Down-Regulates p34 ^{cdc2} ," <i>Cancer Research</i> , Vol. 54, pp. 5531-5534 (Nov. 1, 1994).
		Mariana Resnicoff et al., "Rat Glioblastoma Cells Expressing an Antisense RNA to the Insulin-like Growth Factor-1 (IGF-1) Receptor Are Nontumorigenic and Induce Regression of Wild-Type Tumors," <i>Cancer Research</i> , Vol. 54, pp. 2218-2222 (April 15, 1994).
		Consuelo D'Ambrosio et al., "A Soluble Insulin-like Growth Factor I Receptor That Induces Apoptosis of Tumor Cells <i>in Vivo</i> and Inhibits Tumorigenesis," <i>Cancer Research</i> , Vol. 56, pp. 4013-4020 (Sep. 1, 1996).
		Frauke Rininsland et al., "Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 94, pp. 5854-5859 (May 1997).
		Keiichiro Nakamura et al., "Down-Regulation of the Insulin-like Growth Factor I Receptor by Antisense RNA Can Reverse the Transformed Phenotype of Human Cervical Cancer Cell Lines," <i>Cancer Research</i> , Vol. 60, pp. 760-765 (Feb. 1, 2000).
		Christopher J. Wraight et al., "Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides," <i>Nature Biotechnology</i> , Vol. 18, pp. 521-526 (May 2000).
		Antoni Bayes-Genis et al., "The Insulin-Like Growth Factor Axis a Review of Atherosclerosis and Restenosis," <i>Circulation Research</i> , pp. 125-130 (Feb. 4, 2000).
		Li Long et al., "Loss of the Metastatic Phenotype in Murine Carcinoma Cells Expressing an Antisense RNA to the Insulin-like Growth Factor Receptor," <i>Cancer Research</i> , Vol. 55, pp. 1006-1009 (March 1, 1995).
		Renato Baserga, "Controlling IGF-receptor function: a possible strategy for tumor therapy," <i>BTECH</i> , Vol. 14, pp. 150-152 (1996).
		Renato Baserga et al., "The IGF-I Receptor and Cancer," <i>Endocrine</i> , Vol. 7, No. 1, pp. 99-102 (Aug. 1997).

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 2 of 2	ATTORNEY DOCKET NO.	SERIAL No.
	6170-000010/US	10/591,174
	APPLICANT	
	Jan GUNZINGER et al.	
	FILING DATE	GROUP
	August 30, 2006	TBA



	V.M. Macauley et al., "Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase," <i>Oncogene</i> , Vol. 20, pp. 4029-4040 (2001).
	Marcelina Parrizas et al., "Specific Inhibition of Insulin-Like Growth Factor-1 and Insulin Receptor Tyrosine Kinase Activity and Biological Function by Tyrphostins," <i>Endocrinology</i> , Vol. 138, No. 4, pp. 1427-1433 (1997).
	Galia Blum et al., "Substrate Competitive Inhibitors of IGF-I Receptor Kinase," <i>Biochemistry</i> , Vol. 39, No. 51, pp. 15705-15712 (2000).
	Galia Blum et al., "Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics," <i>J. Biological Chemistry</i> , Vol. 278, No. 42, pp. 40442-40454 (Oct. 17, 2003).
	Lena Kanter-Lewensohn et al., "Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway," <i>Molecular and Cellular Endocrinology</i> , Vol. 165, pp. 131-137 (2000).
	Akira Akahori et al., "Cytotoxic Agents of <i>Thujopsis dolabrata</i> (L. fil.) Sieb et Zucc." <i>Chem. Pharm. Bull.</i> , Vol. 20, No. 6, pp. 1150-1155 (1972).
	Masahiko Kohno et al., "Synthesis of Phenethylamines by Hydrogenation of β -Nitrostyrenes," <i>Chem. Soc. Of Japan</i> , Vol. 63, No. 4, pp. 1252-1254 (1990).
	Stephen A DiBiase et al., "Direct Synthesis of α,β -Unsaturated Nitriles from Acetonitrile and Carbonyl Compounds: Survey, Crown Effects, and Experimental Conditions," <i>J. Org. Chem.</i> , Vol. 44, No. 25, pp. 4640-4649 (1979).
	Melvin Euerby et al., "A Convenient Synthesis of 3-Methylthiobenzaldehyde," <i>Synthetic Communications</i> , Vol. 11, No. 10, pp. 849-851 (1981).
	Makoto Ando et al., "Catalytic Activities of Salicylaldehyde Derivatives. VI.1) Syntheses of Some Dimethylsulfonio Derivatives of Salicylaldehyde," <i>Bull. Of the Chem. Soc. Of Japan</i> , Vol. 51, No. 8, pp. 2435-2436 (1978).
	Michael J. Munchhof et al., "A Novel Route to Chiral, Nonracemic 1-Alkyl- and 1-Aryl-Substituted Tetrahydroisoquinolines. Synthesis of (-)-Salsolidine and (+)-Cryptostyline II," <i>J. Org. Chem.</i> , Vol. 60, pp. 7086-7087 (1995).
	Richard P. Polniaszek et al., "Stereoselective Reductions of Chiral Iminium Ions," <i>Tetrahedron Letters</i> , Vol. 28, No. 39, pp. 4511-4514 (1997).
	Nobuyuki Uematsu et al., "Asymmetric Transfer Hydrogenation of Imines," <i>J. Am. Chem. Soc.</i> , Vol. 118, pp. 4916-4917, (1996).
	Gerrit J. Meuzelaar et al., "Chemistry of Opium Alkaloids, 45 th Improvements in the Total Synthesis of Morphine," <i>Eur. J. Org. Chem.</i> , pp. 2315-2321, (1999).
	Conly L. Rieder et al., "Microtubule disassembly delays the G2-M transition in vertebrates," <i>Current Biology</i> , Vol. 10, No. 17, pp. 1067-1070, (Aug. 2000).
	Michele Rubini et al., "The IGF-I Receptor in Mitogenesis and Transformation of Mouse Embryo Cells: Role of Receptor Number," <i>Experimental Cell Research</i> , Vol. 230, pp. 284-292 (1997).

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.